EFFICACY AND SAFETY OF PREDNISONE-CYCLOPHOSPHAMIDE COMBINATION AS 1ST LINE THERAPY IN 7 PATIENTS WITH ACQUIRED FACTOR-VIII INHIBITORS

被引：0
|
作者：
BERRUT, G
SHOAAY, I
DUPUIS, JM
MAIGRE, M
FRESSINAUD, P
FRESSINAUD, E
机构：
[1] CHU ANGERS,F-49036 ANGERS,FRANCE
[2] CTR HOSP SAUMUR,SAUMUR,FRANCE
[3] CTR TRANSFUS,ANGERS,FRANCE
来源：
THROMBOSIS AND HAEMOSTASIS | 1993年 / 69卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1105 / 1105
页数：1
相关论文
共 50 条
  • [21] Early Nivolumab addition to Regorafenib in patients with hepatocellular carcinoma progressing under 1st line therapy (GOING trial). Interim analysis and safety profile
    Sanduzzi Zamparelli, Marco
    Matilla, Ana M.
    Luis Lledo, Jose
    Munoz Martinez, Sergio
    Varela, Maria
    Inarrairaegui, Mercedes
    Perello, Christie
    Minguez, Beatriz
    Llarch, Neus
    Marquez Perez, Laura
    Guerrero, Antonio
    Iserte, Gemma
    Castano-Garcia, Andres
    Carrion, Laura
    Rimola, Jordi
    Angeles Garcia-Criado, Maria
    Domenech, Gema
    Boix, Loreto
    Bruix, Jordi
    Reig, Maria
    JOURNAL OF HEPATOLOGY, 2022, 77 : S381 - S381
  • [22] Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting
    Zhaozhen Wu
    Haitao Tao
    Sujie Zhang
    Xiao Wang
    Junxun Ma
    Ruixin Li
    Zhefeng Liu
    Jinliang Wang
    Pengfei Cui
    Shixue Chen
    Huang Di
    Ziwei Huang
    Xuan Zheng
    Yi Hu
    Cancer Immunology, Immunotherapy, 2021, 70 : 2971 - 2980
  • [23] Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting
    Wu, Zhaozhen
    Tao, Haitao
    Zhang, Sujie
    Wang, Xiao
    Ma, Junxun
    Li, Ruixin
    Liu, Zhefeng
    Wang, Jinliang
    Cui, Pengfei
    Chen, Shixue
    Di, Huang
    Huang, Ziwei
    Zheng, Xuan
    Hu, Yi
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (10) : 2971 - 2980
  • [24] PHASE II TRIAL OF PANITUMUMAB IN COMBINATION WITH OXALIPLATIN AND CAPECITABINE CHEMOTHERAPY AS 1ST LINE THERAPY IN PATIENTS WITH COLORECTAL CANCER AND ADVANCED LIVER METASTASES: THE METAPAN STUDY
    Leone, F.
    Marino, D.
    Artale, S.
    Cagnazzo, C.
    Cascinu, S.
    Martoni, A. A.
    Sobrero, A.
    Tampellini, M.
    Siena, S.
    Aglietta, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 205 - 206
  • [25] Pilot, Randomized Study Assessing Safety, Tolerability and Efficacy of Simplified LPV/r Maintenance Therapy in HIV Patients on the 1st PI-Based Regimen
    Cahn, Pedro
    Montaner, Julio
    Junod, Patrice
    Patterson, Patricia
    Krolewiecki, Alejandro
    Andrade-Villanueva, Jaime
    Cassetti, Isabel
    Sierra-Madero, Juan
    Casiro, Arnaldo David
    Bortolozzi, Raul
    Lupo, Sergio Horacio
    Longo, Nadia
    Rampakakis, Emmanouil
    Ackad, Nabil
    Sampalis, John S.
    PLOS ONE, 2011, 6 (08):
  • [26] A first community-based, observational study on panitumumab as 1st and 2nd line combination therapy of metastatic colorectal cancer (mCRC) in RAS wildtype patients
    Hebart, H.
    Tessen, H. W.
    Linde, H.
    Koukakis, R.
    Rieth, A.
    Hellebrand, E.
    Reichert, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 73 - 73
  • [27] Molecular and clinical predictors of the efficacy of cetuximab in combination with mFOLFOX6 in 1st line treatment of patients (pts) with metastatic colorectal cancer (mCRC) - subgroup analyses of the CEBIFOX trial
    Kasper, S.
    Ting, S.
    Meiler, J.
    Knipp, H.
    Hoehler, T.
    Reimer, P.
    Steinmetz, T.
    Berger, W.
    Linden, G.
    Worm, K.
    Schmid, K. W.
    Markus, P.
    Paul, A.
    Dechene, A.
    Forsting, M.
    Kostbade, K.
    Trarbach, T.
    Schuler, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 100 - 101
  • [28] First-Line Trastuzumab Plus Epirubicin and Cyclophosphamide Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Cardiac Safety and Efficacy Data From the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) Trial
    Untch, Michael
    Muscholl, Michael
    Tjulandin, Sergei
    Jonat, Walter
    Meerpohl, Hans-Gerd
    Lichinitser, Mikhail
    Manikhas, Alexey G.
    Coumbos, Alexandra
    Kreienberg, Rolf
    du Bois, Andreas
    Harbeck, Nadia
    Jackisch, Christian
    Mueller, Volkmar
    Pauschinger, Matthias
    Thomssen, Christoph
    Lehle, Michaela
    Catalani, Olivier
    Lueck, Hans-Joachim
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) : 1473 - 1480
  • [29] AMALTHEA: A prospective, single-arm study of the Hellenic Cooperative Oncology Group evaluating the efficacy and safety of 1st line FOLFIRI plus Aflibercept in patients with metastatic colorectal cancer
    Pentheroudakis, G.
    Kotoula, V.
    Koliou, G-A.
    Tikas, I.
    Karavasilis, V.
    Samantas, E.
    Aravantinos, G.
    Daskalaki, E.
    Souglakos, I.
    Koumakis, G.
    Efstratiou, I.
    Petraki, C.
    Poulios, C.
    Bafaloukos, D.
    Pectasides, D.
    Vrettou, E.
    Fountzilas, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [30] Open-label, single arm, multicenter, phase 11 study on the efficacy and safety of cetuximab in combination with cisplatin and gemcitabine as 1st-line therapy in patients with advanced non-small cell lung cancer
    Barata, Fernando
    Parente, Barbara
    Teixeira, Encarnacao
    Costa, Agostinho
    Fernandes, Ana
    Pimentel, Francisco L.
    Andrade, Sofia
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S290 - S291
12345